In this episode Dr Harry Gibbs, from The Alfred Hospital in Victoria and Dr Ander Cohen from Guy’s and St Thomas’ Hospital, King’s College in London, UK talk about the toughest bleeds to manage – intracranial bleeding, in patients prescribed anti-thrombotic therapy. How to assess the bleed, how to manage risk factors, and the risk-benefit ratio for recommencing antithrombotic therapy in these patients. Reference information will be shared at the end of this episode.

ELIQUIS® (apixaban)
PBS Information: Authority required (STREAMLINED) Refer to PBS Schedule for full authority information.
PBS Codes: NVAF – 4269 and DVT/Pe initial treatment – 4298 (DVT); 5098 (PE). Other PBS codes differ – please refer to PBS Schedule.
NVAF: Non-valvular atrial fibrillation; DVT: Deep vein thrombosis; PE: Pulmonary embolism.
Before prescribing, please review full ELIQUIS Product Information available from Bristol Myers Squibb Australia by calling 1800 067 567.

Please note that apixaban is contraindicated in patients with clinically significant active bleeding, such as intracranial bleeding and gastrointestinal bleeding. Apixaban is contraindicated in patients with a lesion or condition at significant risk of major bleeding such as recent intracranial haemorrhage. Apixaban should be used in caution in patients with increased risk of haemorrhage, such as history of haemorrhagic stroke. In the event of haemorrhagic complications in a patient receiving apixaban, treatment must be discontinued and the source of bleeding investigated. 

ELIQUIS Consumer Medical Information

ELIQUIS Product Information

References

1. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.

2. King B, Milling T, Gajewski B et al. Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials. Trauma Surg Acute Care Open 2020; 5: e000605.

t360 is an educational program supported by Bristol Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave VIC 3170 and Pfizer Australia Pty Ltd, ABN 50 008 422 348, 151 Clarence Street, Level 15–18, Sydney NSW 2000, and developed by Elixir Healthcare Education Pty Limited, ABN 36 092 185 665, Level 32, 101 Miller Street, North Sydney NSW 2060. ©Copyright 2022 Bristol Myers Squibb–Pfizer Alliance and Elixir Healthcare Education Pty Limited. PP-ELI-AUS-1090.